Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity

• Published in: Journal of Neural Transmission Vol. 121; no. 4; pp. 379 - 383
• Main Authors: Bartl, Jasmin, Müller, Thomas, Grünblatt, Edna, Gerlach, Manfred, Riederer, Peter
• Format: Journal Article
• Language: English
• Published: Vienna Springer Vienna 01-04-2014; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Indans - therapeutic use; Male; Medicine; Medicine & Public Health; Middle Aged; Monoamine Oxidase - blood; Monoamine Oxidase Inhibitors - therapeutic use; Neurology; Neurology and Preclinical Neurological Studies - Short communication; Neurosciences; Parkinson Disease - blood; Parkinson Disease - drug therapy; Psychiatry; Selegiline; MAO-B inhibitors; MAO-A; Rasagiline; Parkinson’s disease
• ISSN: 0300-9564; 1435-1463
• DOI: 10.1007/s00702-013-1120-z

Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.